Cargando…
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-...
Autor principal: | Beatty, Gregory L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063135/ https://www.ncbi.nlm.nih.gov/pubmed/25050204 http://dx.doi.org/10.4161/onci.28327 |
Ejemplares similares
-
Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013) -
Mast cells in pancreatic ductal adenocarcinoma
por: Chang, David Z.
Publicado: (2012) -
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013) -
CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014) -
Extending the chimeric receptor-based T-cell targeting strategy to solid tumors
por: Rossig, Claudia
Publicado: (2013)